

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
20 September 2018 (20.09.2018)



(10) International Publication Number
WO 2018/170109 A1

(51) International Patent Classification:

C07C 235/46 (2006.01) C07C 275/24 (2006.01)

(21) International Application Number:

PCT/US2018/022403

(22) International Filing Date:

14 March 2018 (14.03.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/471,688 15 March 2017 (15.03.2017) US

(71) Applicant: LUNELLA BIOTECH, INC. [CA/CA]; 145
Richmond Road, Ottawa, ON K1Z 1A1 (CA).

(72) Inventors; and

(71) Applicants: LISANTI, Michael, P. [US/US]; 8300
Greensboro Drive, Suite 1100, Tysons, PA 22102 (US).
SOTGIA, Federica [US/US]; 8300 Greensboro Drive,
Suite 1100, Tysons, VA 22102 (US).

(74) Agent: BRADY, Joshua, B.; Williams Mullen, 8300
Greensboro Drive, Suite 1100, Tysons, VA 22102 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: MITORIBOSCINS: MITOCHONDRIAL-BASED THERAPEUTICS TARGETING CANCER CELLS, BACTERIA, AND
PATHOGENIC YEAST

(57) Abstract: The present disclosure relates to inhibitors of mitochondrial function. Methods of screening compounds for mitochon-
drial inhibition are disclosed. Also described are methods of using mitochondrial inhibitors called mitoriboscins - mitochondrial-based
therapeutic compounds having anti-cancer and antibiotic properties - to prevent or treat cancer, bacterial infections, and pathogenic
yeast, as well as methods of using mitochondrial inhibitors to provide anti-aging benefits. Specific mitoriboscin compounds and groups
of mitoriboscins are also disclosed.



WO 2018/170109 A1